Serac Healthcare is highlighting second-phase data about the company's gamma-emitting radiotracer, 99mTc-maraciclatide.
A study published April 29 in the Lancet Obstetrics, Gynaecology & Women's Health suggests that the radiotracer may offer a noninvasive imaging approach for detecting endometriosis, including superficial peritoneal endometriosis (SPE).
The results come from the Detecting Endometriosis inTEgrins Using teChneTium-99m Imaging Study (DETECT), conducted at the Royal United Hospital in Bath, U.K. The study enrolled 20 patients with suspected or confirmed pelvic or thoracic endometriosis using SPECT-CT with intravenous 99mTc-maraciclatide.
The study found that imaging results were concordant with surgical findings in 16 of 19 cases, with endometriosis detected in 14 of 17 surgically positive participants, including two cases of thoracic endometriosis. The researchers reported no false positives were reported. And of 10 participants with SPE who had prior transvaginal ultrasound or MRI within the last 12 months, none had SPE detected by those modalities.
99mTc-maraciclatide has received Fast Track Designation from the U.S. Food and Drug Administration (FDA). Serac said that phase 3 multicenter international studies are planned to begin later in 2026.
